Back to discover
Drug

Dihydroberberine

Research stage
Emerging research
RxNorm2676424
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Dihydroberberine
RxNorm CUI
2676424

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.

Signal transduction and targeted therapy · 2021 · 223 cites
Journals, researchers & institutions
Top journals
  • Signal transduction and targeted therapy1
Leading researchers
  • Cao X1
  • Cong L1
  • Fu J1
  • Gao TL1
  • Han P1
  • Jiang JD1
  • Li XY1
  • Lin Y1
Leading institutions
free-text, unnormalised
  • Department of Immunology & Centre for Immunotherapy1
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines1
  • The First Hospital of Jilin University1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Berberine

Studied across the same disease area as Dihydroberberine in the shared literature.

1 shared disease1 shared paper
Dopamine

Studied across the same disease area as Dihydroberberine in the shared literature.

1 shared disease1 shared paper
Levodopa

Studied across the same disease area as Dihydroberberine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature